Oncimmune Holdings Plc (ONC.L)

17.50 0.00 (0.00%) At close: 01:35PM BST

Oncimmune Holdings Plc

1 Park Row
Leeds LS1 5AB
United Kingdom

https://www.oncimmune.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Martin John Gouldstone	CEO & Director	N/A	N/A	1967
Mr. Martin Hudson	Fin. Director	N/A	N/A	N/A
Mr. Ron Kirschner	COO, Gen. Counsel & Company Sec.	N/A	N/A	1979
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP	Chief Scientific Officer	N/A	N/A	N/A
Ms. Cléa Rosenfeld	Head of Investor Relations	N/A	N/A	N/A
Mr. Maarten Brusse	Chief Commercial Officer of Asia	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc has a collaboration with Siemens Healthineers AG. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

Corporate governance

Oncimmune Holdings Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.